The Potential Game-Changer: Pfizer and BioNTech’s mRNA Vaccine Shows Promising Results

Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19 Overview Pfizer Inc. and BioNTech SE have announced positive topline results from a Phase 1/2 study evaluating the safety, tolerability, and immune responses of their mRNA-based combination vaccine candidates for influenza and COVID-19. The study demonstrated robust immune responses […]